Total for the last 12 months
number of access : ?
number of downloads : ?
ID 117233
Author
Bando, Hiroshi Kanaiso Hospital|Tokushima University|Japan Low Carbohydrate Diet Promotion Association KAKEN Search Researchers
Yamashita, Hisako Kanaiso Hospital
Kato, Yoshinobu Kanaiso Hospital
Ogura, Katsunori Kanaiso Hospital
Kato, Yoshikane Kanaiso Hospital
Kanazawa, Setsuko Kanaiso Hospital
Keywords
Type 2 diabetes
Obesity
Oral semaglutide
Weight
Content Type
Journal Article
Description
Background: Obesity and Type 2 Diabetes (T2D) are crucial problems worldwide. Oral semaglutide (Rybelsus) was introduced to medical practice for Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA). Case presentation: The patient is 24-year-old female with obesity (BMI 39.3 kg/m2), T2D and fatty liver. Results: She started and increased Rybelsus from 3mg, 7mg to 14mg/day each 4 weeks. She showed significant efficacy for 4 months as HbA1c 6.3% to 5.6% and weight 107kg to 103kg, without Gastrointestinal Adverse Events (GIAEs). Discussion: Rybelsus is provided just after waking up, and kept >30 min fasting period. Longer fasting time may contribute current effect.
Journal Title
Journal of Obesity and Diabetes
ISSN
2638812X
Publisher
Edelweiss Publications
Volume
5
Issue
1
Start Page
11
End Page
14
Published Date
2022-06-22
Rights
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences